Table 3.
Association of 5-unit increase in Body Mass Index with overall and breast cancer-specific mortality, by characteristics of the tumor
| Overall mortality | Breast cancer mortality | ||||||
|---|---|---|---|---|---|---|---|
| N | Deaths | HRa | 95% CI | Deaths | HRb | 95% CI | |
| Stage | |||||||
| Metastatic | 1814 | 604 | 1.06 | (0.96–1.18) | 377 | 1.11 | (0.97–1.27) |
| Non-metastatic | 8021 | 1005 | 1.18 | (1.10–1.27) | 516 | 1.11 | (0.99–1.24) |
| Heterogeneity p-value | 0.336 | 0.963 | |||||
| Estrogen receptor status | |||||||
| ER + | 7723 | 1124 | 1.15 | (1.07–1.23) | 533 | 1.14 | (1.03–1.25) |
| ER- | 1718 | 434 | 1.04 | (0.92–1.18) | 287 | 1.05 | (0.89–1.24) |
| Heterogeneity p-value | 0.051 | 0.135 | |||||
| Hormone receptor status | |||||||
| PR + | 5183 | 636 | 1.19 | (1.09–1.30) | 285 | 1.03 | (0.89–1.18) |
| PR - | 2676 | 529 | 1.04 | (0.93–1.17) | 311 | 1.09 | (0.94–1.27) |
| Heterogeneity p-value | 0.038 | 0.872 | |||||
| HER2 status | |||||||
| HER2 + | 870 | 167 | 1.05 | (0.87–1.26) | 116 | 0.92 | (0.72–1.17) |
| HER2- | 3679 | 488 | 1.20 | (1.08–1.33) | 276 | 1.16 | (1.01–1.33) |
| Heterogeneity p-value | 0.160 | 0.073 | |||||
Abbreviations: HR, Hazard Ratio; CI, Confidence Interval
Heterogeneity test: Likelihood Ratio Test
aHazard Ratios from the multivariate Cox regression model
bSubdistribution Hazard Ratios from the multivariable Fine and Gray regression model